REGENERON PHARMACEUTICALS, INC. 10-Q

Item 5. Other Information During the three months ended June 30, 2024, no director or executive officer adopted , modified, or terminated any trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. Item 6. Exhibits (a) Exhibits Exhibit Number Description 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. 32 Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. 101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the registrant's Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023; (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2024 and 2023; (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2024 and 2023; (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023; and (v) the notes to the registrant's Condensed Consolidated Financial Statements. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 78 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REGENERON PHARMACEUTICALS, INC. Date: August 1, 2024 By: /s/ Christopher Fenimore Christopher Fenimore Senior Vice President, Finance and Chief Financial Officer (Duly Authorized Officer) 79